In the tissue samples of ovarian cancer patients sensitive to PARP inhibitors, 34.7% (41/114) showed "High" expression of RORα, 26.3% (31/114) showed "Moderate" expression, 23.7% (28/114) showed "Weak" expression, and 15.3% (18/114) showed "Negative" expression (Figure 8B). Here, RORA is linked to ovarian cancer.